Juergen A. Martens
Keine laufenden Positionen mehr
Profil
Juergen A.
Martens worked as VP-Pharmaceutical Technology Development at Nektar Therapeutics from 2000 to 2005.
He then worked as Chief Operating Officer at MannKind Corp.
from 2015 to 2016, and as Chief Operations & Technology Officer at Neos Therapeutics, Inc. from 2016 to 2017.
Martens received his undergraduate degree from Mannheim Technical College, and his graduate and doctorate degrees from Philipps University of Marburg.
He also received a graduate degree from the University of Pennsylvania.
Ehemalige bekannte Positionen von Juergen A. Martens
| Unternehmen | Position | Ende |
|---|---|---|
| NEOS THERAPEUTICS, INC. | Geschäftsführer | 30.06.2017 |
| MANNKIND CORPORATION | Geschäftsführer | 18.03.2016 |
| NEKTAR THERAPEUTICS | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2005 |
Ausbildung von Juergen A. Martens
| University of Pennsylvania | Graduate Degree |
| Philipps University of Marburg | Doctorate Degree |
| Mannheim Technical College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| NEKTAR THERAPEUTICS | Health Technology |
| MANNKIND CORPORATION | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Neos Therapeutics, Inc.
 Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
